Vericel’s Q3 2026 Earnings: Revenue Climbs, Guidance Raised, and Cash Keeps Pacing the Pace
Vericel Corporation (NASDAQ: VCEL) announced third-quarter 2026 results that stitch together a stronger top line, margin discipline, and a cash-rich balance sheet. The company posted EPS of $0.27 on a diluted basis and lifted its full-year revenue forecast, signaling that growth drivers across MACI and Burn Care are converging with ongoing cash generation.
Overview
Vericel reported a robust Q3, with total net revenue rising 26% to $85.4 million. Net income climbed 179% to $14.2 million, or $0.27 per diluted share (EPS). The company highlighted a non-GAAP adjusted EBITDA of $25.2 million, representing 30% of revenue, alongside a gross margin of 73%. Operating cash flow reached $17.7 million and free cash flow stood at $15.7 million. The balance sheet remains notably levered toward cash and investments, with roughly $235.6 million on hand and no debt.
The press release notes these results in the context of ongoing growth drivers in Vericel’s two main franchises: MACI and Burn Care. There is no explicit earnings surprise versus an EPS consensus published in the filing, so readers should monitor upcoming Street estimates for a formal compare-and-contrast in the next earnings cycle.
Third Quarter 2026 Financial Highlights
- Total net revenue: up 26% to $85.4 million
- MACI net revenue: up 21% to $67.4 million
- Burn Care net revenue: up 52% to $18.0 million
- Epicel revenue: $12.7 million; NexoBrid revenue: $5.3 million
- Gross margin: 73%
- Net income: $14.2 million, or $0.27 per diluted share (EPS)
- Non-GAAP adjusted EBITDA: $25.2 million (30% of revenue)
- Operating cash flow: $17.7 million
- Free cash flow: $15.7 million
- Cash and investments: $235.6 million; no debt
These results undergird a broader narrative: Vericel is widening its operating cushion while sustaining growth across its two core platforms. The combination of MACI’s growth and burn-care strength is helping the company push toward a more durable profitability profile.
Outlook and Guidance
Vericel raised its full-year revenue guidance to a range of $344 million to $346 million and increased the Adjusted EBITDA margin guidance to 28%. In practical terms, the company is signaling confidence in continued demand across its portfolio and the ability to translate top-line gains into cash flow and margin expansion. A conference call was scheduled for that day at 8:30 a.m. Eastern Time to discuss the results and the outlook.
From an analyst’s lens, the move to lift the revenue forecast intersects with the EPS trajectory and the potential for an earnings surprise in future quarters, should demand hold and cost leverage materialize. The revenue forecast, paired with a 28% EBITDA margin target, paints a scenario where Vericel could extend its cash-generating profile even as growth remains front-and-center.
Business Mix and Sector Implications
MACI remains the largest revenue contributor, but Burn Care is gaining momentum, highlighted by a 52% year-over-year increase to $18.0 million and with Epicel and NexoBrid contributing meaningful add-ons. The burn-care revenue mix is particularly notable because it reflects adoption dynamics for complex therapies outside the orthobiologics core, potentially offering a signaling path for how Vericel’s platform could scale in adjacent segments.
In the broader context of its sector peers—biotech-adjacent cell therapies and regenerative medicine—Vericel’s ability to harvest operating cash flow while expanding gross margin is a constructive sign. The balance sheet posture—substantial liquidity and no debt—affords the company flexibility in pursuing pipeline investments, capacity expansion, or potential tuck-in acquisitions that could accelerate the cadence of EPS growth and the earnings surprise potential if the market underestimates the margin uplift or the speed of MACI and burn-care adoption.
Risks and Considerations
As with any growth company in specialized therapies, Vericel faces potential headwinds around payer reimbursement, pricing pressure, and execution risks in scaling manufacturing to meet higher demand. The concurrent strength in MACI and Burn Care could be sensitive to shifts in clinical adoption, competing therapies, and regulatory or supply-chain disruptions. Investors will be watching not just the headline revenue gains, but the trajectory of EPS and the degree to which EBITDA margins sustain at or above guided levels amid ongoing investment needs.
Takeaway
VCEL’s Q3 narrative blends a clean top-line beat with a demonstrable path to higher profitability. The EPS figure of $0.27 accompanies a robust cash flow cadence, and the raised revenue forecast anchors a narrative where Vericel could widen its earnings power while preserving balance-sheet strength. For sector peers, the message is less about a single product and more about the combination of portfolio diversification, operating leverage, and liquidity that underpins a durable earnings profile. If the market is looking for a hint of the next earnings surprise, a sustained EBITDA margin near 30% and a continued 20%–plus MACI growth could do the talking.